• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

    3.825 -0.085 (-2.17%)
    Streaming Delayed Price Updated: 12:34 PM EDT, May 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Myriad Genetics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    News headline image
    Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know
    A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
    Via StockStory
    Topics Artificial Intelligence Stocks
    News headline image
    Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 3, 2025 ↗
     
    Via Benzinga
    News headline image
    Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
    100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    The Top 5 Analyst Questions From Myriad Genetics’s Q3 Earnings Call
    Myriad Genetics’ third quarter saw revenue and adjusted profit in line with Wall Street expectations, but the market reacted negatively due to ongoing challenges in average revenue per test and... 
    Via StockStory
    Topics Earnings
    News headline image
    Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Why Myriad Genetics (MYGN) Stock Is Down Today
    Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 19.3% in the morning session after it reported mixed third-quarter results that were overshadowed by a weak earnings outlook. 
    Via StockStory
    Topics Economy Government World Trade
    News headline image
    MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market Headwinds
    Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year... 
    Via StockStory
    News headline image
    Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops
    Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year... 
    Via StockStory
    News headline image
    Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings
    Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to expect. 
    Via StockStory
    News headline image
    Exploring Myriad Genetics's Earnings Expectations ↗
     
    Via Benzinga
    News headline image
    New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
    Faster initial remission and response, persistent benefit over six months 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    1 Stock Under $10 Worth Your Attention and 2 Facing Challenges
    Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
    Via StockStory
    News headline image
    Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    2 Unpopular Stocks That Deserve a Second Chance and 1 That Underwhelm
    Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
    Via StockStory
    News headline image
    Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
    The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    3 Cash-Burning Stocks with Open Questions
    While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to... 
    Via StockStory
    News headline image
    Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know
    A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
    Via StockStory
    Topics Economy Government World Trade
    News headline image
    Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
    From D S Simon
    Via GlobeNewswire
    News headline image
    A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack
    Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Myriad Genetics (NASDAQ:MYGN) and its peers. 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    3 Unprofitable Stocks That Fall Short
    Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
    Via StockStory
    News headline image
    Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    3 Small-Cap Stocks That Concern Us
    Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
    Via StockStory
    News headline image
    Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way
    The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
    The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
    Via StockStory
    News headline image
    3 Russell 2000 Stocks with Open Questions
    The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
    Via StockStory
    Topics Regulatory Compliance
    News headline image
    Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    News headline image
    New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
    Results published in the Journal of Clinical Psychopharmacology 
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    14 15 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.